Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Tesamorelin Dosing Protocol: 10 mg Vial — Extended Supply Dosing Guide

Tesamorelin 10 mg vial guide — provides 5 days of the FDA-approved 2 mg/day dose from a single reconstitution, reducing handling frequency.

Quickstart highlights

Tesamorelin's FDA-approved 2 mg/day protocol demonstrated 15.2% visceral fat reduction at 26 weeks in Phase 3 (Falutz et al., 2010).

  • Concentration: 2 mg/mL (10 mg vial + 5 mL bacteriostatic water).
  • At 2 mg/mL: 2 mg = 100 units (full 1 mL) once daily — the FDA-approved Egrifta SV dose.
  • One 10 mg vial provides exactly 5 daily doses at 2 mg — reconstitute twice weekly.
  • Phase 3 (Falutz et al.): 2 mg/day x 26 weeks reduced visceral fat 15.2% vs. 0.7% placebo.
  • Refrigerate; use within 28 days.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-4100050Once daily1 mg — 50 units; 10 mg vial provides 10 doses at this level (10 days)
5-262000100Once daily2 mg — 100 units (FDA-approved dose); 10 mg vial provides 5 daily doses (5 days)

Reconstitution steps

  1. Draw 5 mL bacteriostatic water in two 2.5 mL draws; inject slowly down the vial wall.
  2. Swirl gently until powder dissolves fully; do not shake.
  3. Final concentration: 2 mg/mL. Label with date; refrigerate at 2–8 °C. Use within 28 days.
  4. One 10 mg vial covers 5 daily doses at 2 mg — plan reconstitution twice weekly at the 2 mg/day maintenance dose.

Supplies needed

12-week plan

  • 12 vials
  • 84 syringes
  • 60 mL bac water
  • 84 alcohol swabs

26-week plan

  • 37 vials
  • 182 syringes
  • 185 mL bac water
  • 182 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Reduce visceral adipose tissue through twice-weekly reconstitution of tesamorelin 10 mg vials at the 2 mg/day FDA-approved dose, providing 5 days of injections per reconstitution event.

Cycle length: 26 weeks on.

Off-cycle: 8 weeks off; measure IGF-1 and visceral fat surrogate (waist circumference) before resuming.

Storage & handling

Lyophilized: store below 25 °C or refrigerate. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days. At 2 mg/day: one 10 mg vial lasts 5 days — reconstitute approximately twice weekly.

Injection & tracking tips

  • Reconstitute twice weekly at the 2 mg/day dose — one 10 mg vial covers exactly 5 daily injections.
  • Inject at the same time daily (morning preferred) in the abdomen, 2 inches from the navel; rotate within quadrants.
  • Store used vials cap-side down in the refrigerator door; inspect for cloudiness before each draw.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Measure waist circumference weekly as a visceral fat proxy.
  • Track IGF-1 every 8 weeks; target upper-normal for age.
  • Monitor fasting glucose monthly; tesamorelin can increase glucose by 5–10 mg/dL in insulin-resistant patients.
Log your cycle in the calculator →

How this works & references

Tesamorelin's FDA-approved 2 mg/day protocol demonstrated 15.2% visceral fat reduction at 26 weeks in Phase 3 (Falutz et al., 2010). The 10 mg vial offers a modest logistical advantage over 5 mg vials at the 2 mg/day dose: reconstitution every 5 days versus every 2.5 days, roughly halving the number of reconstitution events and associated sterility risks.

Frequently asked questions

How many 10 mg vials do I need for a 26-week protocol at 2 mg/day?
182 total doses at 2 mg = 364 mg total. At 10 mg/vial: 364 ÷ 10 = 36.4 — approximately 37 vials for the full 26-week protocol. Budget accordingly or consider the 20 mg vial for fewer reconstitutions.
Is the 10 mg vial significantly more convenient than the 5 mg vial?
At 2 mg/day: 5 mg vial lasts 2.5 days (reconstitute every 2.5 days = ~2.8 times per week); 10 mg vial lasts 5 days (reconstitute twice per week). The 10 mg vial reduces reconstitution events by approximately 50%, which is meaningful over a 26-week protocol.
Can tesamorelin be used for weight loss in non-HIV patients?
Off-label use for visceral fat reduction in non-HIV patients occurs in practice, but the Phase 3 evidence base is specific to HIV-associated lipodystrophy. The mechanism (visceral fat lipolysis via GH/IGF-1 elevation) is independent of HIV status, suggesting plausible efficacy — but no Phase 3 data in non-HIV populations exists.
Does tesamorelin improve triglycerides as well as visceral fat?
Yes — the Falutz Phase 3 trial showed triglyceride reduction as a secondary endpoint: approximately 50 mg/dL reduction from baseline at 26 weeks in the tesamorelin arm. The mechanism is GH-mediated enhancement of lipoprotein lipase activity and VLDL clearance.
What are the signs of excessive tesamorelin dose?
Signs of supraphysiological GH elevation include: carpal tunnel syndrome (wrist/finger tingling), joint pain (arthralgia), edema (ankle swelling), and elevated fasting glucose. If IGF-1 exceeds 350 ng/mL for age, reduce dose to 1 mg/day and reassess.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.